Michael David Garrison, Executive Vice President and President of Medical (TASE:PMCN) at Becton Dickinson & Co. (NYSE:BDX), recently sold 597 shares of the company’s common stock. The shares were sold at an average price of $236.51, amounting to a total transaction value of $141,196. Following this sale, Garrison holds 5,544 shares directly.
This transaction was executed under a pre-established Rule 10b5-1 trading plan, which Garrison adopted on August 2, 2024. The filing was signed by Donna Kalazdy, holding power of attorney for Garrison, and was reported on January 21, 2025.
In other recent news, Becton Dickinson (BD), a global medical technology firm, reported robust financial results for its Fourth Quarter and Full-Year Fiscal 2024. The company saw a revenue growth of 7.4% in Q4, and a full-year organic revenue increase of 5%. Adjusted diluted earnings per share (EPS) also experienced an 11.4% rise, reaching $13.14 for the full year. Despite challenges in China and the Bioscience-Pharma sector, BD's MedTech and Diagnostics segments grew by 5.9%, with BD Medical's biologic drug delivery sales surpassing $1 billion.
In terms of future developments, BD anticipates revenue between $21.9 billion and $22.1 billion for FY '25, with adjusted diluted EPS guidance of $14.25 to $14.60. The company also announced a $1 billion share repurchase plan and increased its dividend by 9.5%. However, BD remains cautious about the Chinese market, expecting a mid-single-digit decline due to value-based procurement pressures.
Lastly, BD is optimistic about the continued growth of key products such as Alaris into FY '25, and the integration of the Advanced Patient Monitoring business is expected to drive growth. The company also outlined its capital allocation strategies, including a focus on R&D investment for the integration of Advanced Patient Monitoring, with funding allocated for fiscal year 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.